Immune System News and Research

RSS

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Newly discovered receptor may help in early diagnosis and treatment for sepsis

Sepsis, or septicaemia, is a devastating disease that is difficult to diagnose early and for which treatment options are limited. The number of deaths from sepsis exceeds those from lung cancer, and from breast and bowel cancer combined.

4 Dec 2013

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

For some, the disease multiple sclerosis attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages-even before the onset of physical signs.

3 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

Research proves effectiveness of vaccine against leishmaniasis

The disease is considered endemic in the south states of Mexico. A research executed in the Autonomous University of Yucatan (UADY) has successfully proved, in test animals, the effectiveness of a vaccine that immunizes the organism against leishmaniasis, an ailment transmitted through insects very similar to mosquitos and mainly presents symptoms in the skin, liver or spleen.

3 Dec 2013

ATN-224 inhibitor reduces tumor sizes in mouse model of lung adenocarcinoma

Many cancers have adapted to cope with high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1, is overproduced in lung adenocarcinomas and has been implicated as a target for chemotherapy.

3 Dec 2013

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Scientists have moved a step closer to an "obesity drug" that may block the effects of diets high in sugar and fats. In a new research report published in the December 2013 issue of The FASEB Journal, scientists show that there is an abnormal amount of an inflammatory protein called PAR2 in the abdominal fat tissue of overweight and obese humans and rats.

3 Dec 2013

Oxygen levels play critical role in determining effectiveness of anti-inflammatory drugs

A new research discovery published in the December 2013 issue of the Journal of Leukocyte Biology yields an important clue toward helping curb runaway inflammation. Oxygen levels play a critical role in determining the severity of the inflammatory response and ultimately the effectiveness of anti-inflammatory drugs.

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

Insomnia symptoms linked to increased mortality

Certain aspects of insomnia are associated with an increased risk for mortality, shows an analysis of a large cohort of US men.

2 Dec 2013

USC scientists show gene-environment interaction augments risk for developing autism

Exposure to air pollution appears to increase the risk for autism among people who carry a genetic disposition for the neurodevelopmental disorder, according to newly published research led by scientists at the Keck School of Medicine of the University of Southern California.

2 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

People living with chronic fatigue are set to benefit with the opening next week (Dec 2), of the National Centre for Neuroimmunology and Emerging Diseases at Griffith University.

30 Nov 2013

Garden-Gateway believes chronic sufferers can cope with holiday stress

The holidays are a time of high stress for all of us. This is especially true for the many Californians who suffer from chronic illness or disease. It's well documented that stress can aggravate a wide range of chronic ailments, both physical and psychological, such as back pain, cancer, PTSD or immune system deficiency.

30 Nov 2013

Food safety tips for people with HIV/AIDS

December 1, 2013 is World AIDS Day and while the connection between HIV/AIDS (Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) and food safety may not seem obvious, it's actually crucial.

30 Nov 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

Immune System News and Research

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Newly discovered receptor may help in early diagnosis and treatment for sepsis

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Researchers offer promise of strategy for curing HIV infection

Research proves effectiveness of vaccine against leishmaniasis

ATN-224 inhibitor reduces tumor sizes in mouse model of lung adenocarcinoma

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Oxygen levels play critical role in determining effectiveness of anti-inflammatory drugs

Newly identified protein could prove promising new drug target for AIDS

Insomnia symptoms linked to increased mortality

USC scientists show gene-environment interaction augments risk for developing autism

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

Garden-Gateway believes chronic sufferers can cope with holiday stress

Food safety tips for people with HIV/AIDS

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News